Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis

Status Active, not recruiting

Clinical Trial Summary

Clinical Trial Description

Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus and had a diagnosis of systemic lupus erythematosus, and had active renal disease as defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K). Efficacy and safety analyses included all patients who received at least one dose of study drug. The baricitinib 4 mg dose suggestive to significantly improved the signs and symptoms of active systemic lupus erythematosus in patients who were not adequately controlled despite standard of care therapy, with a safety profile consistent with previous studies of baricitinib. This study provides the idea for future trials of JAK1/2 inhibition with baricitinib as a new potential oral therapy for ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05432531
Study type	Interventional
Source	Assiut University
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	June 1, 2022
Completion date	April 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02936375` - The Iguratimod Effect on Lupus Nephritis (IGeLU)	Phase 2
Completed	`NCT03597464` - Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin	Phase 3
Recruiting	`NCT01226147` - Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis	Phase 2
Completed	`NCT01206569` - Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis	Phase 4
Active, not recruiting	`NCT00569101` - A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis	Phase 2
Terminated	`NCT00368264` - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )	Phase 2/Phase 3
Completed	`NCT00298506` - Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)	N/A
Completed	`NCT00371319` - Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis	Phase 4
Completed	`NCT00094380` - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)	Phase 1/Phase 2
Terminated	`NCT04376827` - A Study of Guselkumab in Participants With Active Lupus Nephritis	Phase 2
Completed	`NCT03610516` - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.	Phase 2
Recruiting	`NCT03526042` - Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis	N/A
Withdrawn	`NCT03859570` - Pentoxifylline in Lupus Nephritis	Phase 4
Completed	`NCT03664908` - Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?	N/A
Completed	`NCT01085097` - A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis	Phase 2
Active, not recruiting	`NCT05704088` - SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients	Phase 4
Not yet recruiting	`NCT06429800` - A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis	Phase 1
Recruiting	`NCT02226341` - ACTHar in the Treatment of Lupus Nephritis	Phase 4
Recruiting	`NCT02453997` - Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis	N/A
Completed	`NCT01470183` - Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients	N/A